SCHEMBL13639098

SCHEMBL13639098

Nc1cc(Oc2cccc(N=O)c2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.47
NOS1 P29475 2/20 0.47
NOS2 P35228 2/20 0.47
ALOX5AP P20292 2/20 0.39
FEN1 P39748 2/20 0.39
MET P08581 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MITF O75030 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
GFER P55789 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NLRP1 Q9C000 1/20 0.38
NOD2 Q9HC29 1/20 0.38
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
MAOB P27338 1/20 0.37
SCN9A Q15858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12499981 0.85 NOS3 (0.49) NOS3NOS1NOS2ALOX5APFEN1
SCHEMBL14684302 0.80 MAOB (0.60) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL15500373 0.80 SMN1; SMN2 (0.48) MEN1KMT2AMITFALDH1A1GAA
SCHEMBL30046762 0.78 NOS3 (0.55) NOS3NOS1NOS2ALOX5APFEN1
SCHEMBL14256891 0.77 MAOB (0.50) MEN1KMT2AMITFALDH1A1GAA
SCHEMBL13635718 0.77 NOS3 (0.50) NOS3NOS1NOS2ALOX5APFEN1
SCHEMBL10139164 0.76 MEN1 (0.54) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL797972 0.76 MET (0.54) NOS3NOS1NOS2ALOX5APFEN1
SCHEMBL13038567 0.76 NOS3 (0.46) NOS3NOS1NOS2ALOX5APFEN1
SCHEMBL21481993 0.74 LOXL2 (0.50) NOS3NOS1NOS2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX NOS3 99/4885NOS1 264/4885NOS2 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.